Modern management of severe staphylococcal disease.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002245:Carbon Dioxide / Q000378:metabolism; D002247:Carbon Isotopes; D002511:Cephalosporins / Q000627:therapeutic use; D003428:Cross Infection / Q000453:epidemiology; D005060:Europe; D006784:Hospitals, Teaching; D006801:Humans; D007557:Israel; D010403:Penicillin Resistance; D010406:Penicillins / Q000009:adverse effects / Q000627:therapeutic use; D011485:Protein Binding; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology / Q000628:therapy*; D013210:Staphylococcus / Q000302:isolation & purification / Q000378:metabolism; D013997:Time Factors; D014481:United States; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002247:Carbon Isotopes; D002511:Cephalosporins; D010406:Penicillins; D002245:Carbon Dioxide; D014640:Vancomycin